Vincerx Pharma Shares to Reverse Split on Tuesday, January 28th (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINC)’s stock is going to reverse split before the market opens on Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 27th.

Vincerx Pharma Stock Performance

VINC traded down $0.03 during trading on Friday, reaching $0.10. The company’s stock had a trading volume of 7,380,350 shares, compared to its average volume of 4,778,677. The company’s fifty day moving average price is $0.22 and its 200-day moving average price is $0.46. The company has a market capitalization of $3.50 million, a price-to-earnings ratio of -0.10 and a beta of 1.48. Vincerx Pharma has a 52-week low of $0.10 and a 52-week high of $9.37.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners lowered their target price on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its holdings in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the period. Marshall Wace LLP owned about 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. Institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.